The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
What is now needed are larger, prospective, randomized trials that can establish causality, characterize which women benefit most, identify the optimal timing and formulation of each therapy, and track outcomes across the full range of health domains this article has examined, metabolic, cardiovascular, cognitive, and functional
Ensure the pharmacy is in-network with the patients plan or inform patients they may need to seek reimbursement if out-of-network
Silva specializes in evidence-based weight management, including GLP-1 and GIP therapies like tirzepatide to improve metabolic and hormonal health
